Skip to main content

Defining Diabetic Retinopathy Severity

  • Chapter
  • First Online:
Diabetic Retinopathy

Abstract

The fundus abnormalities seen in diabetic retinopathy can conceptually be split into three categories – those findings resulting from leaking microvasculature (hemorrhages, lipid exudates, retinal edema); those findings resulting from structural damage to the microvasculature wall (microaneurysms); and those findings resulting from ischemia with a subsequent overproduction of vascular growth factors (cottonwool patches, intraretinal microvascular abnormalities [IRMA], preretinal neovascularization, fibrous proliferation, and vitreous hemorrhage). The severity of each of these findings can be classified and quantified based on the degree of retina involvement, e.g., the number of microaneurysms and hemorrhages in each quadrant or photographic field, the area of retina affected by neovascular tissue or IRMA, the area of macula involved with retinal thickening. Classification schemes are a means to categorize the varying degrees of such findings to facilitate communication.As with all specialized languages, the value of these languages depends upon who is speaking to whom. The ultimate goal of classification schemes is to provide a system to improve patient care. This may be achieved initially by precise communication among researchers to define categories by which the natural history and subsequent response to intervention(s) can be identified. Once these research goals have been achieved these classification schemes should be understandable and reproducible by practicing clinicians. If not, then modification of these classification schemes is desirable to allow clinicians to communicate among themselves and with their patients the expected results of therapies demonstrated to be beneficial in clinical trials. One should realize that the goals of communication between researchers may be different from the goals of communication between clinicians and may likewise be different from the goals of communication between clinician and patient. Evolution of classification schemes is desirable dependent upon who is communicating with whom.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Davis MD, Norton EWD, Meyers FL. The Airlie classification of diabetic retinopathy. In: Goldberg MF, Fine SL, eds. Symposium on the Treatment of Diabetic Retinopathy. Washington, DC: US Government Printing Office; 1969:7–22. USPHS Publication #1890.

    Google Scholar 

  2. The Diabetic Retinopathy Study Research Group. A modification of the Airlie House classification of diabetic retinopathy: DRS Report 7. Invest Ophthalmol Vis Sci. 1981; 21:210–226.

    Google Scholar 

  3. Early Treatment Diabetic Retinopathy Study Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: An extension of the modified Airlie house classification: ETDRS Report Number 10. Ophthalmology. 1991; 98: 786–806.

    Google Scholar 

  4. Early Treatment Diabetic Retinopathy Study Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report Number 12. Ophthalmology. 1991; 98: 823–833.

    Google Scholar 

  5. Early Treatment Diabetic Retinopathy Study Research Group. Early treatment Diabetic Retinopathy Study Design and baseline patient characteristics: ETDRS Report Number 7. Ophthalmology. 1991;98:741–756.

    Google Scholar 

  6. Wilkinson CP, Ferris FL III, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–1682.

    Article  CAS  PubMed  Google Scholar 

  7. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS Report Number 9. Ophthalmology. 1991;98:766–785.

    Google Scholar 

  8. Patz A, Smith RE. The ETDRS and diabetes 2000. Ophthalmology. 1991;98:730–740.

    Google Scholar 

  9. Early Treatment Diabetic Retinopathy Study Group. Effects of aspirin treatment on diabetic retinopathy: ETDRS Report Number 8. Ophthalmology. 1991;98:758.

    Google Scholar 

  10. Gonzales ME, Gonzales C, Stern MP, et al. Concordance in diagnosis of diabetic retinopathy by fundus photography between retina specialists and a standardized reading center. Arch Med Res. 1995;26:127–131.

    Google Scholar 

  11. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS Report Number 4. Int Ophthalmol Clin. 1987;27:265–272.

    Google Scholar 

  12. Browning DJ, McOwen MD, Bowen RM Jr, et al. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology. 2004;111:712–715.

    Article  PubMed  Google Scholar 

  13. Browning DJ, Altaweel MM, Bressler NM, et al. Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol. 2008;146:649–655.

    Article  PubMed  Google Scholar 

  14. Gangnon RE, Davis MD, Hubbard LD, et al. A severity scale for diabetic macular edema (DME) developed from ETDRS data. IOVS. 2008;49:5041–8.

    Google Scholar 

  15. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms: ETDRS Report Number 11. Ophthalmology. 1991;98:807–822.

    Google Scholar 

  16. Early Treatment Diabetic Retinopathy Study Research Group. Fluorescein angiographic risk factors for progression of diabetic retinopathy: ETDRS Report Number 13. Ophthalmology. 1991;98:834–840.

    Google Scholar 

  17. Kylstra JA, Brown JC, Jaffe GJ, et al. The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology. 1999;106:2068–2073.

    Article  CAS  PubMed  Google Scholar 

  18. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: ETDRS Report Number 2. Ophthalmology. 1987;94:761–774.

    Google Scholar 

  19. Abu El, Asrar AM, Morse PH. Laser photocoagulation control of diabetic macular edema without fluorescein angiography. Br J Ophthalmol. 1991;75:97–99.

    Article  Google Scholar 

  20. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860–1867.

    Google Scholar 

  21. Friberg TR, Gupta A, Yu J, et al. Ultrawide angle fluorescein angiographic imaging: a comparison to conventional digital acquisition systems. Ophthalmic Surg Lasers Imaging. 2008;39:304–311.

    Article  PubMed  Google Scholar 

  22. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study Research Group. Effects of intensive therapy on the microvascular complications of type I diabetes mellitus. JAMA 2002;287:2563–2569.

    Google Scholar 

  23. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1988;352:854–865.

    Google Scholar 

  24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J. 1998;317:703–713.

    Google Scholar 

  25. Lyons TJ, Jenkins AJ, Zhen D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–918.

    Article  PubMed  Google Scholar 

  26. Kostraba JN, Klein R, Dorman JS, et al. The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol. 1991;133:381–391.

    CAS  PubMed  Google Scholar 

  27. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS Report Number 7. Ophthalmology. 1991;98:741–756.

    Google Scholar 

  28. Diabetes Control and Complications Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of diabetic retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–983.

    Google Scholar 

  29. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions Complications Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial. Arch Ophthalmol. 2008;126:1707–1715.

    Google Scholar 

  30. Diabetic Retinopathy Clinical Research Network. Comparison of modified-ETDRS and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469–480.

    Google Scholar 

  31. Ferris F. Early photocoagulation in patients with type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–537.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keye Wong .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Wong, K. (2010). Defining Diabetic Retinopathy Severity. In: Browning, D. (eds) Diabetic Retinopathy. Springer, New York, NY. https://doi.org/10.1007/978-0-387-85900-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-85900-2_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-85899-9

  • Online ISBN: 978-0-387-85900-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics